Distribution and Antifungal Susceptibility of Yeasts Isolates from Intensive Care Unit Patients

Overview

Journal Folia Microbiol (Praha)

Publisher Springer

Specialty Microbiology

Date 2017 Apr 1

PMID 28361459

Citations 4

Authors

Vladimir Hrabovsky

Victoria Takacova

Eva Schreterova

Lydia Pastvova

Zuzana Hrabovska

Katarina curova

Leonard Siegfried

Affiliations

Soon will be listed here.

Abstract

Yeasts frequently colonize non-sterile sites in the body. The aim of the study was to determine distribution in clinical samples and antifungal susceptibility to five antifungals. From January 2013 through June 2015, 800 isolates were obtained from intensive care unit patients. Candida albicans (58.9%), Candida glabrata (20.4%), Candida krusei (8.6%), and Candida parapsilosis (3.6%) were the leading species. Majority of the C. albicans isolates were susceptible to the fluconazole. Elevated voriconazole minimal inhibitory concentrations (MICs) were observed in isolates exhibiting high fluconazole MICs, most frequently in C. glabrata. Isolates with echinocandins MICs suggesting reduced susceptibility were only sporadic cases with the exception of Trichosporon spp. The amphotericin B MICs were slightly higher for some C. krusei.

Citing Articles

Clinical outcomes of antifungal therapy on Candida pulmonary colonisation in immunocompetent patients with invasive ventilation: a systematic review and meta-analysis.

Li L, Su S, Yang H, Xie H BMJ Open. 2024; 14(10):e083918.

PMID: 39438107 PMC: 11499771. DOI: 10.1136/bmjopen-2024-083918.

Virulence and resistance factors of Nakaseomyces glabratus (formerly known as Candida glabrata) in Europe: A systematic review.

Rodriguez-Cerdeira C, Pinto-Almazan R, Saunte D, Hay R, Szepietowski J, Szepietowsk J J Eur Acad Dermatol Venereol. 2024; 39(2):377-388.

PMID: 39136534 PMC: 11760688. DOI: 10.1111/jdv.20273.

Pichia kudriavzevii (Candida krusei): A systematic review to inform the World Health Organisation priority list of fungal pathogens.

Nguyen T, Kim H, Stocker S, Kidd S, Alastruey-Izquierdo A, Dao A Med Mycol. 2024; 62(6).

PMID: 38935911 PMC: 11210618. DOI: 10.1093/mmy/myad132.

Promising antifungal activity of new oxadiazole against Candida krusei.

Faria D, Sakita K, Capoci I, Arita G, Rodrigues-Vendramini F, de Oliveira Junior A PLoS One. 2020; 15(1):e0227876.

PMID: 31935275 PMC: 6959663. DOI: 10.1371/journal.pone.0227876.

Trichosporon inkin meningitis in Northeast Brazil: first case report and review of the literature.

Pipolo Milan E, Silva-Rocha W, de Almeida J, Fernandes T, de Araujo Prudente A, de Azevedo M BMC Infect Dis. 2018; 18(1):470.

PMID: 30227852 PMC: 6145100. DOI: 10.1186/s12879-018-3363-7.

References

Espinel-Ingroff A, Arendrup M, Pfaller M, Bonfietti L, Bustamante B, Canton E . Interlaboratory variability of Caspofungin MICs for Candida spp. Using CLSI and EUCAST methods: should the clinical laboratory be testing this agent?. Antimicrob Agents Chemother. 2013; 57(12):5836-42. PMC: 3837874. DOI: 10.1128/AAC.01519-13. View

Cuenca-Estrella M, Gomez-Lopez A, Cuesta I, Zaragoza O, Mellado E, Rodriguez-Tudela J . Frequency of voriconazole resistance in vitro among Spanish clinical isolates of Candida spp. According to breakpoints established by the Antifungal Subcommittee of the European Committee on Antimicrobial Susceptibility Testing. Antimicrob Agents Chemother. 2011; 55(4):1794-7. PMC: 3067132. DOI: 10.1128/AAC.01757-10. View

Mayr A, Aigner M, Lass-Florl C . Anidulafungin for the treatment of invasive candidiasis. Clin Microbiol Infect. 2011; 17 Suppl 1:1-12. DOI: 10.1111/j.1469-0691.2010.03448.x. View

Falagas M, Roussos N, Vardakas K . Relative frequency of albicans and the various non-albicans Candida spp among candidemia isolates from inpatients in various parts of the world: a systematic review. Int J Infect Dis. 2010; 14(11):e954-66. DOI: 10.1016/j.ijid.2010.04.006. View

Fridkin S . The changing face of fungal infections in health care settings. Clin Infect Dis. 2005; 41(10):1455-60. DOI: 10.1086/497138. View

White T, Holleman S, Dy F, Mirels L, Stevens D . Resistance mechanisms in clinical isolates of Candida albicans. Antimicrob Agents Chemother. 2002; 46(6):1704-13. PMC: 127245. DOI: 10.1128/AAC.46.6.1704-1713.2002. View

Krcmery Jr V, Kovacicova G . Longitudinal 10-year prospective survey of fungaemia in Slovak Republic: trends in etiology in 310 episodes. Slovak Fungaemia study group. Diagn Microbiol Infect Dis. 2000; 36(1):7-11. DOI: 10.1016/s0732-8893(99)00096-6. View

Guinea J . Global trends in the distribution of Candida species causing candidemia. Clin Microbiol Infect. 2014; 20 Suppl 6:5-10. DOI: 10.1111/1469-0691.12539. View

Shoham S, Marwaha S . Invasive fungal infections in the ICU. J Intensive Care Med. 2009; 25(2):78-92. DOI: 10.1177/0885066609355262. View

10.

Snydman D . Shifting patterns in the epidemiology of nosocomial Candida infections. Chest. 2003; 123(5 Suppl):500S-3S. DOI: 10.1378/chest.123.5_suppl.500s. View

11.

Dimopoulos G, Velegraki A, Falagas M . A 10-year survey of antifungal susceptibility of candidemia isolates from intensive care unit patients in Greece. Antimicrob Agents Chemother. 2008; 53(3):1242-4. PMC: 2650580. DOI: 10.1128/AAC.01368-08. View

12.

Comert F, Kulah C, Aktas E, Eroglu O, Ozlu N . Identification of Candida species isolated from patients in intensive care unit and in vitro susceptibility to fluconazole for a 3-year period. Mycoses. 2007; 50(1):52-7. DOI: 10.1111/j.1439-0507.2006.01309.x. View

13.

Peman J, Canton E, Linares-Sicilia M, Rosello E, Borrell N, Ruiz-Perez-de-Pipaon M . Epidemiology and antifungal susceptibility of bloodstream fungal isolates in pediatric patients: a Spanish multicenter prospective survey. J Clin Microbiol. 2011; 49(12):4158-63. PMC: 3232947. DOI: 10.1128/JCM.05474-11. View

14.

Vandeputte P, Ferrari S, Coste A . Antifungal resistance and new strategies to control fungal infections. Int J Microbiol. 2011; 2012:713687. PMC: 3236459. DOI: 10.1155/2012/713687. View

15.

Pfaller M, Diekema D, Andes D, Arendrup M, Brown S, Lockhart S . Clinical breakpoints for the echinocandins and Candida revisited: integration of molecular, clinical, and microbiological data to arrive at species-specific interpretive criteria. Drug Resist Updat. 2011; 14(3):164-76. DOI: 10.1016/j.drup.2011.01.004. View

16.

Kanafani Z, Perfect J . Antimicrobial resistance: resistance to antifungal agents: mechanisms and clinical impact. Clin Infect Dis. 2008; 46(1):120-8. DOI: 10.1086/524071. View

17.

Fournier P, Schwebel C, Maubon D, Vesin A, Lebeau B, Foroni L . Antifungal use influences Candida species distribution and susceptibility in the intensive care unit. J Antimicrob Chemother. 2011; 66(12):2880-6. DOI: 10.1093/jac/dkr394. View

18.

Garbino J, Lew D, Romand J, Hugonnet S, Auckenthaler R, Pittet D . Prevention of severe Candida infections in nonneutropenic, high-risk, critically ill patients: a randomized, double-blind, placebo-controlled trial in patients treated by selective digestive decontamination. Intensive Care Med. 2002; 28(12):1708-17. DOI: 10.1007/s00134-002-1540-y. View

19.

Ferreira D, Grenouillet F, Blasco G, Samain E, Henon T, Dussaucy A . Outcomes associated with routine systemic antifungal therapy in critically ill patients with Candida colonization. Intensive Care Med. 2015; 41(6):1077-88. DOI: 10.1007/s00134-015-3791-4. View

20.

Bruder-Nascimento A, Camargo C, Sugizaki M, Sadatsune T, Montelli A, Mondelli A . Species distribution and susceptibility profile of Candida species in a Brazilian public tertiary hospital. BMC Res Notes. 2010; 3:1. PMC: 2830941. DOI: 10.1186/1756-0500-3-1. View